Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

EX-DR TB EX-DR TB: Elimination of Extensive Drug Resistance Through better Regimens for TB

Coordinator
Ludwig-Maximilians-Universitaet Muenchen, Germany
Runs
1 October 2025 to 30 September 2031
Status
Running
EU funding
€7.1m
Total cost
€7.1m
Partners
17 organisations in 12 countries
Type
Research and Innovation Action
Grant agreement
101190913

What the project is doing

In the project's own words, from its summary on CORDIS.

In 2022, the World Health Organization (WHO) recommended bedaquiline (BDQ)-based, all-oral regimens including pretomanid (Pa), linezolid (L), and moxifloxacin (M) (BPaLM), lasting 6-9 months However, BDQ-resistance is rising dramatically and threatening these advancements. Mozambique has reported BDQ resistance in 28% of MDR-TB isolates in 2024, up from 3% in 2016 and at 10% in South Africa (Ndjeka N, personal communication).

Spread of BDQ-R TB must be slowed by antibiotic stewardship through more rapid, accurate, and near-patient diagnostics, and optimized management; until new treatment options with drugs that have no pre-existing resistance or are able to overcome small shifts in MIC will be available. The proposed EX-DR TB project includes diagnostic capacity strengthening, adapting treatment recommendations, and a trial of two new regimens composed of new drugs.

The EDCTP EX-DR TB project will: 1.Develop treatment recommendations by a Delphi process with stakeholders - to make use of targeted next generation sequencing (tNGS) that is being rolled out by most national TB programmes - this will yield short-term benefit for patients and NTPs; and will slow the spread of BDQ-resistant bacteria;2.Rigorously evaluate two treatment regimens composed of new drugs, in a phase 3 clinical trial conducted to the highest regulatory standard – this will be the main focus of EX-DR TB.

The trial objective will be to move a regimen towards regulatory approval by FDA and/or EMA, and WHO if supported by results. Thus, EX-DR will create the tools for containing the nascent epidemic of BDQ-R TB and make them available to healthcare providers and TB Programmes. EX-DR TB will be embedded in a larger coalition of funders and partners focused on implementing and evaluating diagnostics and performing the trial beyond of the EDCTP funded area.

Topics

Who is involved

OrganisationCityCountryRole
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyCoordinator
Forschungszentrum Borstel Leibniz LungenzentrumBorstelGermanyParticipant
Klinikum Der Ludwig-Maximilians-Universitat MunchenMunchenGermanyThird party
Glaxosmithkline Investigacion Y Desarrollo SLTres Cantos MadridSpainParticipant
Ospedale San Raffaele SRLMilanoItalyParticipant
LigaChem Biosciences, Inc.DaejeonSouth KoreaAssociatedpartner
Institutia Medico-Sanitara Publica - Institutul De Pneumologie ""chiril Draganiuc""""ChisinauMoldovaParticipant
Instituto Nacional de SaúdeMarracueneMZParticipant
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant
Uppsala UniversitetUppsalaSwedenParticipant
Baylor College of Medicine Childrens Foundation EswatiniMbabaneSZParticipant
City St Georges University of LondonLondonUnited KingdomParticipant
University College LondonLondonUnited KingdomParticipant
Global Alliance for Tb Drug Development Non Profit OrganisationNew YorkUnited StatesAssociatedpartner
The Regents of the University of CaliforniaOaklandUnited StatesAssociatedpartner
University of Cape TownRondeboschSouth AfricaParticipant
Wits Health Consortium (pty) LtdJohannesburgSouth AfricaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI